1358 (1358) Fair Value & Analysis

Healthcare · Market cap HK$1.6B

1 1358 1358 · HK

PriceHK$1.07

Fair ValueHK$2.06

Upside+92.5%

Quality61/100

Watch 1358 for free — get notified when fair value or trend changes. Watch for free

Evidence: Medium Range HK$1.25 – HK$2.09

Fair value as of: Jul 2, 2026

From 24 valuation models · updated today

Share price −7.6% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.9915 – HK$1.53 · fair‑value band HK$1.25 – HK$2.09 · the HK$1.07 price screens below the HK$2.06 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1358 (1358) currently trades at HK$1.07, while our model-based Fair Value estimate is HK$2.06 — implying the stock looks roughly 92.5% undervalued today. We read business quality at 61/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

Over the trailing twelve months, 1358 generated revenue of HK$824M at a net margin of 11.5%. Revenue declined 5.0% year over year. It earns a return on equity of 2.8%. The balance sheet holds a net cash position of HK$1.8B. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$824M

Revenue growth (YoY) -5.0%

Net margin 11.5%

Return on equity 2.8%

Free cash flow HK$136M FY2025

P/E ratio 15.6

More key figures

Operating margin 10.3%

EPS (TTM) HK$0.0400

Dividend yield 5.3%

EPS growth (YoY) -65.1%

Net cash HK$1.8B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1358 reported revenue of HK$824M in FY2025 versus HK$271M in FY2021, a compound +32.0%/yr. Reported net income was HK$94.4M in FY2025, compounding −40.2%/yr from FY2021.

Revenue +32.0%/yr

FY21 HK$271M

FY22 HK$537M

FY23 HK$675M

FY24 HK$769M

FY25 HK$824M

Net income −40.2%/yr

FY21 HK$739M

FY22 HK$106M

FY23 HK$153M

FY24 HK$151M

FY25 HK$94.4M

Is 1358 fairly valued? → Check now

Similar stocks

6 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Intuitive Surgical, Inc ISRG	$412.02	$165.35	-60%
EssilorLuxottica Société anonyme ESLOF	$192.00	$126.51	-34%
HOYA Corporation HOCPY	$168.16	$96.16	-43%
Medline Inc MDLN	$34.71	$30.15	-13%
Becton, Dickinson and Company BDX	$140.71	$104.17	-26%
Alcon Inc ALC	$66.58	$36.99	-44%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1358 (1358) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$2.06 versus a price of HK$1.07 — about +93% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 1358?

Our model-based fair value for 1358 is HK$2.06 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$1.07.

What is the quality score of 1358?

1358 has a Quality Score of 61/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1358 (1358)?

1358 reported trailing-twelve-month revenue of about HK$824M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1358?

The net profit margin of 1358 is about 11.5%, meaning it keeps roughly 11.5% of revenue as net income. Based on the latest reported figures.

Does 1358 pay a dividend?

1358 currently shows a dividend yield of about 5.27% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.